Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/1/2000


1.		Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UKMC-95GI24CB NCI-H97-1184

Last Modified: 4/20/2007


2.		Phase II Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in Combination With Interleukin-2 and/or Sargramostim (GM-CSF) in Adults With Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-97-C-0141F NCI-T96-0078, T96-0078, NCT00019331

Last Modified: 4/20/2007


3.		Phase I Study of Carcinoembryonic Antigen Peptide-1 (CAP) and DetoxPC for Adenocarcinomas of the Gastrointestinal Tract, Breast, and Lung (Summary Last Modified 09/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-96-C-0139 NCI-NMOB-9305, NCI-T96-0058N, T96-0058

Last Modified: 4/20/2007


4.		Phase I Study of Recombinant Carcinoembryonic Antigen (CEA) Vaccinia Virus Vaccine With Post Vaccination CEA Peptide Challenge in Patients With Malignant Solid Tumors (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18				NCI				MUSC-6124 NCI-T95-0044, T95-0044

Last Modified: 12/27/2008 First Published: 8/1/1999


5.		Phase I Pilot Adjuvant Study of Immunological Parameters Associated With Skin Testing and Vaccination With Autologous Lung Tumor Associated Antigen Plus DetoxPC in Patients With Curatively Resected Stage I, II, or IIIA Non-Small Cell Lung Cancer or Stage I or II Mesothelioma (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				20 to 70				NCI				RPCI-DS-96-25 NCI-G99-1551, NCT00003974

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute